Respiratory Clinical Trials

Statistical methods in respiratory trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All respiratory trials

757 results

• CAN-COVIDIndependent statistical analysis of CAN-COVID, a randomized phase 3 study of canakinumab versus placebo for cytokine release syndrome in participants with COVID-19-induced pneumonia, including its primary binary endpoint, logistic regression, odds ratio,…Phase 3Results postedn = 454NCT04362813
• Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 38NCT00400803
• Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 1/2Results postedn = 1NCT02748889
• Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 22NCT00281827
• Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 186NCT00003869
• Cardio-pulmonary Rehabilitation and Sleep Quality: Complete Statistical AnalysisIndependent statistical analysis of Cardio-pulmonary Rehabilitation and Sleep Quality: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04668599).Phase NAResults postedn = 106NCT04668599
• CARDIOSA-12Independent statistical analysis of Hypoglossal Nerve Stimulation on Cardiovascular Outcomes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03359096).Phase NAResults postedn = 63NCT03359096
• Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors – Effect of Fenofibrate: Complete Statistical AnalysisIndependent statistical analysis of Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 12NCT05080192
• CARDSIndependent statistical analysis of Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04427280).Phase NAResults postedn = 153NCT04427280
• CASTIndependent statistical analysis of Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00767039).Phase 4Results postedn = 52NCT00767039
• CATCH-UPIndependent statistical analysis of Community-engaged Approaches to Testing in Community and Healthcare Settings for Underserved Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 323NCT04870307
• CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 312NCT05236270
• Catheter Placement for Hepatic Hydrothorax: Complete Statistical AnalysisIndependent statistical analysis of Catheter Placement for Hepatic Hydrothorax: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02595567).Phase NAResults postedn = 25NCT02595567
• CCBCRISIS04Independent statistical analysis of Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 26NCT05166876
• CESARIndependent statistical analysis of CESAR, a prospective cohort of acute cardiology referrals in an ambulatory day-hospital setting, including its study population, endpoint definition, planned proportion analysis, and statistical interpretation.n = 25,000NCT07675434
• Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA – NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC): primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 27NCT00673738
• CHANGEIndependent statistical analysis of "CHANGE COVID-19 Severity": primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04941703).Phase 1/2Results postedn = 23NCT04941703
• Characteristics of Pts Initiating Spiriva Respimat in Asthma: Complete Statistical AnalysisIndependent statistical analysis of Characteristics of Pts Initiating Spiriva Respimat in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03692676).Phase NAResults postedn = 116,133NCT03692676
• CHASE 2Independent statistical analysis of A Study in Asthmatic Children (6 toPhase 2Results postedn = 54NCT01136655
• Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…Phase 2Results postedn = 7NCT03871153
• Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01102231).Phase 2Results postedn = 106NCT01102231
• Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 71NCT00979212
• Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 70NCT00409006
• Chemotherapy for Patients With Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy for Patients With Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00380718).Phase 4Results postedn = 33NCT00380718
• Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 5NCT00402883
• CHEST-2Independent statistical analysis of CHEST-2, a phase 3 long-term extension study of riociguat in patients with pulmonary hypertension, including trial design, registered endpoints, safety results, planned statistical interpretation, and methodological context.Phase 3Results postedn = 237NCT00910429
• Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China: Complete Statistical AnalysisIndependent statistical analysis of Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04853238).Phase NAResults postedn = 1,507NCT04853238
• Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 65NCT00079040
• Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 160NCT03382561
• Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19): Complete Statistical AnalysisIndependent statistical analysis of Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 17NCT04348500
• Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma: Complete Statistical AnalysisIndependent statistical analysis of Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02260492).Phase 1Results postedn = 879NCT02260492
• Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 248NCT01436071
• Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 435NCT04918771
• Clinical Study of the Immunogenicity of GSK Biologicals’ Influenza Vaccine GSK2186877A in People Aged 65 Years or Older: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 192NCT00765076
• Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 10,644NCT01964989
• Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1Results postedn = 55NCT04310579
• CODEXIndependent statistical analysis of Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 4Results postedn = 137NCT00489853
• Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2/3Results postedn = 36NCT00227617
• Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 46NCT00280150
• Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD): Complete Statistical AnalysisIndependent statistical analysis of Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 360NCT00696020
• Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial): Complete Statistical AnalysisIndependent statistical analysis of Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial): primary endpoint results, effect estimate…Phase 2Results postedn = 47NCT04173507
• Common Safety Follow-up Trial of Tecemotide (L-BLP25): Complete Statistical AnalysisIndependent statistical analysis of Common Safety Follow-up Trial of Tecemotide (L-BLP25): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01423760).Phase NAResults postedn = 27NCT01423760
• Communities Fighting COVID Return to School: Complete Statistical AnalysisIndependent statistical analysis of Communities Fighting COVID Return to School: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05150860).Phase NAResults postedn = 852NCT05150860
• Community Care for Croup (RCT): Complete Statistical AnalysisIndependent statistical analysis of Community Care for Croup (RCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01042145).Phase 4Results postedn = 87NCT01042145
• COMPANIONIndependent statistical analysis of Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 119NCT05330312
• Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia: Complete Statistical AnalysisIndependent statistical analysis of Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 47NCT03734822
• Comparative Effectiveness of COPD Treatments: Complete Statistical AnalysisIndependent statistical analysis of Comparative Effectiveness of COPD Treatments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03376295).Phase NAResults postedn = 3,954NCT03376295
• Comparative Effectiveness Study of Bubble CPAP Devices in the NICU: Complete Statistical AnalysisIndependent statistical analysis of Comparative Effectiveness Study of Bubble CPAP Devices in the NICU: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02392806).Phase NAResults postedn = 43NCT02392806
• Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS: Complete Statistical AnalysisIndependent statistical analysis of Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 360NCT00519636
• Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism: Complete Statistical AnalysisIndependent statistical analysis of Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 18NCT01458639

← All therapeutic areas